New technologies for diabetes: a review of the present and the future

International Journal of Pediatric Endocrinology

Rubina A Heptulla¹  Neesha Ramchandani² 

[1] Albert Einstein College of Medicine, Division of Pediatric Endocrinology, Bronx, NY, 10461, USA;The Children’s Hospital at Montefiore, Division of Pediatric Endocrinology & Diabetes, 3415 Bainbridge Ave, Bronx, NY, 10467, USA

关键词: SmartInsulin;    Insulin pill;    Insulin patch;    Inhaled insulin;    New therapies;    Blood glucose meter;    Insulin pump;    Continuous glucose monitoring;    Diabetes technology;   

Others  :  813438
DOI  :  10.1186/1687-9856-2012-28

 received in 2012-08-17, accepted in 2012-10-15,  发布年份 2012

【 摘 要 】

This review summarizes the technologies in use and in the pipeline for the management of diabetes. The review focuses on glucose meters, continuous glucose monitoring devices, insulin pumps, and getting clinicians connected to technologies. All information presented can be found in the public domain, and was obtained from journal articles, websites, product review tables in patient publications, and professional conferences. The technology concerns, ongoing development and future trends in this area are also discussed.

【 授权许可】

   
2012 Ramchandani and Heptulla; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Health D: Blood Glucose Meters. 2012. available from http://www.diabeteshealth.com/media/pdfs/PRG0112/BloodGlucoseMeters.pdf webcite). 2012, pp. table of currently available BG meters
• [2]Ginsberg BH: Factors affecting blood glucose monitoring: sources of errors in measurement. J Diabetes Sci Technol 2009, 3:903-913.
• [3]Lyon ME, Baskin LB, Braakman S, Presti S, Dubois J, Shirey T: Interference studies with two hospital-grade and two home-grade glucose meters. Diabetes Technol Ther 2009, 11:641-647.
• [4]Heinemann L: Quality of glucose measurement with blood glucose meters at the point-of-care: relevance of interfering factors. Diabetes Technol Ther 2010, 12:847-857.
• [5]Freestyle InsuLinx website: Freestyle InsuLinx website. available from http://www.abbottdiabetescare.co.uk/your-products/freestyle-insulinx webcite
• [6]Meet the meter that actually wants to get to know you better. 2012. available from http://www.onetouch.com/verio webcite
• [7]DiabetesNet. HealthPia Glucophone. 2011. available from http://www.diabetesnet.com/node/303 webcite
• [8]GlucoTel Makes Glucose Monitoring Easy. available from http://www.bodytel.com/en/patient/products/glucotel.html webcite
• [9]iBG Star website. available from http://www.bgstar.com/web/ibgstar webcite
• [10]InDuo website. available from http://www.lifescan.com/company/about/press/prinduo/ webcite
• [11]Brighter One website. available from http://www.brightercompany.com/video webcite). pp. combination BG meter and insulin pen
• [12]Numerous Non-Invasive Glucose Monitors Under Development. 2011. available from http://www.bigmountaindrugs.com/blog/index.php/2011/05/numerous-non-invasive-glucose-monitors-under-development/ webcite). May 11
• [13]Telcare website. available from http://telcare.com/ webcite
• [14]Telcare connectivity information. available from http://mobihealthnews.com/12226/fda-clears-telcares-3g-blood-glucose-meter/ webcite
• [15]GlucoTrack website. available from http://www.integrity-app.com/description.html webcite
• [16]Tendrich A (Ed): In A T. The tiny tattoo that could (monitor blood sugar in florescent light). 2011. accessed from http://www.diabetesmine.com/2011/08/the-tiny-tattoo-that-could-monitor-blood-sugar-in-florescent-light.html webcite)
• [17]J V. Fluorescent nanosensor tattoo monitors glucose under the iPhone's glare. 2011. available from http://www.engadget.com/2011/07/21/fluorescent-nanosensor-tattoo-monitors-glucose-under-the-iphone/ webcite
• [18]Grove Instruments website. available from http://groveinstruments.com/ webcite
• [19]Grove Instruments technology. available from http://groveinstruments.com/grovetechnology.html webcite
• [20]InLight Solutions website. available from http://www.inlightsolutions.com/prod-glu.html webcite
• [21]LighTouch website. available from http://www.lightouchmedical.com/glucosemonitor.html webcite
• [22]I-Sugarx website. available from http://www.freedom-meditech.com/index.php?submenu=Endo&src=gendocs&ref=Professional%20-%20Common%20GM%20Product%20Description&category=Professional webcite
• [23]BA P. Augmented Reality in a Contact Lens ieee spectrum: BA P. Augmented Reality in a Contact Lens ieee spectrum. 2009. available from http://spectrum.ieee.org/biomedical/bionics/augmented-reality-in-a-contact-lens/0 webcite
• [24]Tura A, Maran A, Pacini G: Non-invasive glucose monitoring: assessment of technologies and devices according to quantitative criteria. Diabetes Res Clin Pract 2007, 77:16-40.
• [25]Diabetech (R) Launches GlucoMON (R)-RT Real-Time Monitoring for Remote Diabetes Caregivers. 2008. available from http://www.prweb.com/releases/2008/02/prweb678523.htm webcite). Feb. 6
• [26]G O. GlucoMon Remote Diabetic Monitoring medGadget. 2008. available from http://medgadget.com/2008/02/glucomon_remote_diabetic_monitoring.html webcite). Feb. 7
• [27]Cerner online diabetes tool. available from http://www.openclinical.org/publicApp_CernerDiabetes webcite
• [28]Diasend website. available from http://diasend.com/site/index.php?option=com_content&task=view&id=12&Itemid=105&lang=en webcite
• [29]CareLink Personal Therapy Management Software for Diabetes. available from carelink.minimed.com
• [30]Mamkin I, Ten S, Bhandari S, Ramchandani N: Real-time continuous glucose monitoring in the clinical setting: the good, the bad, and the practical. J Diabetes Sci Technol 2008, 2:882-889.
• [31]Kovatchev BP, Gonder-Frederick LA, Cox DJ, Clarke WL: Evaluating the accuracy of continuous glucose-monitoring sensors: continuous glucose-error grid analysis illustrated by TheraSense Freestyle Navigator data. Diabetes Care 2004, 27:1922-1928.
• [32]Bode B, Gross K, Rikalo N, Schwartz S, Wahl T, Page C, et al.: Alarms based on real-time sensor glucose values alert patients to hypo- and hyperglycemia: the guardian continuous monitoring system. Diabetes Technol Ther 2004, 6:105-113.
• [33]Gandrud LM, Xing D, Kollman C, Block JM, Kunselman B, Wilson DM, et al.: The Medtronic Minimed Gold continuous glucose monitoring system: an effective means to discover hypo- and hyperglycemia in children under 7 years of age. Diabetes Technol Ther 2007, 9:307-316.
• [34]Diabetes Research in Children Network Study G: The accuracy of the CGMS in children with type 1 diabetes: results of the diabetes research in children network (DirecNet) accuracy study. Diabetes Technol Ther 2003, 5:781-789.
• [35]Garg S, Zisser H, Schwartz S, Bailey T, Kaplan R, Ellis S, et al.: Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care 2006, 29:44-50.
• [36]Maia FF, Araujo LR: [Accuracy, utility and complications of continuous glucose monitoring system (CGMS) in pediatric patients with type 1 diabetes]. J Pediatr 2005, 81:293-297.
• [37]Deiss D, Bolinder J, Riveline JP, Battelino T, Bosi E, Tubiana-Rufi N, et al.: Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care 2006, 29:2730-2732.
• [38]Bailey TS, Zisser HC, Garg SK: Reduction in hemoglobin A1C with real-time continuous glucose monitoring: results from a 12-week observational study. Diabetes Technol Ther 2007, 9:203-210.
• [39]Hirsch IB, Abelseth J, Bode BW, Fischer JS, Kaufman FR, Mastrototaro J, et al.: Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study. Diabetes Technol Ther 2008, 10:377-383.
• [40]Study G, Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, Juvenile Diabetes Research Foundation Continuous Glucose Monitoring, et al.: Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008, 359:1464-1476.
• [41]Raccah D, Sulmont V, Reznik Y, Guerci B, Renard E, Hanaire H, et al.: Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the RealTrend study. Diabetes Care 2009, 32:2245-2250.
• [42]T D: Continuous glucose monitoring. New Orleans, LA: American Diabetes Association 69th Scientific Sessions; 2009.
• [43]Study G, Buckingham B, Beck RW, Tamborlane WV, Xing D, Kollman C, Diabetes Research in Children Network, et al.: Continuous glucose monitoring in children with type 1 diabetes. J Pediatr 2007, 151:388-393. 93 e1-2
• [44]Study G, Weinzimer S, Xing D, Tansey M, Fiallo-Scharer R, Mauras N, Diabetes Research in Children Network, et al.: Prolonged use of continuous glucose monitors in children with type 1 diabetes on continuous subcutaneous insulin infusion or intensive multiple-daily injection therapy. Pediatr Diabetes 2009, 10:91-96.
• [45]Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, et al.: Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010, 363:311-320.
• [46]Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, et al.: Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase. Diabetes Care 2011, 34:2403-2405.
• [47]Ramchandani N, Arya S, Ten S, Bhandari S: Real-life utilization of real-time continuous glucose monitoring: the complete picture. J Diabetes Sci Technol 2011, 5:860-870.
• [48]Symphony tCGM system. available from http://www.echotx.com/symphony-tcgm-system.shtml webcite
• [49]Prelude system. (available from http://www.echotx.com/prelude-skinprep-system.shtml webcite). pp. Prelude is used with the Symphony tCGM system to prep the skin
• [50]Solianis/Biovotion AG website. available from http://www.biovotion.com/technology-parameters-multisensor.phtml webcite
• [51]Saxl T, Khan F, Ferla M, Birch D, Pickup J: A fluorescence lifetime-based fibre-optic glucose sensor using glucose/galactose-binding protein. Analyst 2011, 136:968-972.
• [52]Conference Proceedings: Ninth Annual Diabetes Technology Meeting, San Francisco, CA. 2009.
• [53]Wang W, Li Z, Zheng W, Dong B, Li S, Wang C: A novel non-enzymatic glucose sensor based on nickel (II) oxide electrospun nanofibers. J Nanosci Nanotechnol 2010, 10:7537-7540.
• [54]Nie H, Yao Z, Zhou X, Yang Z, Huang S: Nonenzymatic electrochemical detection of glucose using well-distributed nickel nanoparticles on straight multi-walled carbon nanotubes. Biosens Bioelectron 2011, 30:28-34.
• [55]Johannessen E, Krushinitskaya O, Sokolov A, Philipp H, Hoogerwerf A, Hinderling C, et al.: Toward an injectable continuous osmotic glucose sensor. J Diabetes Sci Technol 2010, 4:882-892.
• [56]Joseph JI, Hipszer B: Real-time glucose monitoring in the hospital: future or now? Adv Surg 2010, 44:165-184.
• [57]Kowalski AJ: Can we really close the loop and how soon? Accelerating the availability of an artificial pancreas: a roadmap to better diabetes outcomes. Diabetes Technol Ther 2009, 11(Suppl 1):S113-S119.
• [58]Tamborlane WV: Fulfilling the promise of insulin pump therapy in childhood diabetes. Pediatr Diabetes 2006, 7(Suppl 4):4-10.
• [59]Willi SM, Planton J, Egede L, Schwarz S: Benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes. J Pediatr 2003, 143:796-801.
• [60]Boland EA, Grey M, Oesterle A, Fredrickson L, Tamborlane WV: Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care 1999, 22:1779-1784.
• [61]Sulli N, Shashaj B: Long-term benefits of continuous subcutaneous insulin infusion in children with Type 1 diabetes: a 4-year follow-up. Diabet Med J Br Diabet Assoc 2006, 23:900-906.
• [62]Jakisch BI, Wagner VM, Heidtmann B, Lepler R, Holterhus PM, Kapellen TM, et al.: Comparison of continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI) in paediatric Type 1 diabetes: a multicentre matched-pair cohort analysis over 3 years. Diabet Med J Br Diabet Assoc 2008, 25:80-85.
• [63]Scrimgeour L, Cobry E, McFann K, Burdick P, Weimer C, Slover R, et al.: Improved glycemic control after long-term insulin pump use in pediatric patients with type 1 diabetes. Diabetes Technol Ther 2007, 9:421-428.
• [64]Danne T, von Schutz W, Lange K, Nestoris C, Datz N, Kordonouri O: Current practice of insulin pump therapy in children and adolescents - the Hannover recipe. Pediatr Diabetes 2006, 7(Suppl 4):25-31.
• [65]Tamborlane WV, Sikes KA, Steffen AT, Weinzimer SA: Continuous subcutaneous insulin infusion (CSII) in children with type 1 diabetes. Diabetes Res Clin Pract 2006, 74(Suppl 2):S112-S115.
• [66]Tamborlane WV, Fredrickson LP, Ahern JH: Insulin pump therapy in childhood diabetes mellitus: guidelines for use. Treat Endocrinol 2003, 2:11-21.
• [67]Pickup JC, Sutton AJ: Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med J Br Diabet Assoc 2008, 25:765-774.
• [68]Hanas R, Adolfsson P: Insulin pumps in pediatric routine care improve long-term metabolic control without increasing the risk of hypoglycemia. Pediatr Diabetes 2006, 7:25-31.
• [69]Danne T, Battelino T, Kordonouri O, Hanas R, Klinkert C, Ludvigsson J, et al.: A cross-sectional international survey of continuous subcutaneous insulin infusion in 377 children and adolescents with type 1 diabetes mellitus from 10 countries. Pediatr Diabetes 2005, 6:193-198.
• [70]Doyle EA, Weinzimer SA, Steffen AT, Ahern JA, Vincent M, Tamborlane WV: A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care 2004, 27:1554-1558.
• [71]Jeha GS, Karaviti LP, Anderson B, Smith EO, Donaldson S, McGirk TS, et al.: Insulin pump therapy in preschool children with type 1 diabetes mellitus improves glycemic control and decreases glucose excursions and the risk of hypoglycemia. Diabetes Technol Ther 2005, 7:876-884.
• [72]Saha ME, Huuppone T, Mikael K, Juuti M, Komulainen J: Continuous subcutaneous insulin infusion in the treatment of children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab JPEM 2002, 15:1005-1010.
• [73]Shehadeh N, Battelino T, Galatzer A, Naveh T, Hadash A, de Vries L, et al.: Insulin pump therapy for 1–6 year old children with type 1 diabetes. Israel Med Assoc J IMAJ 2004, 6:284-286.
• [74]Weinzimer SA, Doyle EA, Steffen AT, Sikes KA, Tamborlane WV: Rediscovery of insulin pump treatment of childhood type 1 diabetes. Minerva Med 2004, 95:85-92.
• [75]Weinzimer SA, Ahern JH, Doyle EA, Vincent MR, Dziura J, Steffen AT, et al.: Persistence of benefits of continuous subcutaneous insulin infusion in very young children with type 1 diabetes: a follow-up report. Pediatrics 2004, 114:1601-1605.
• [76]Maahs DM, Horton LA, Chase HP: The use of insulin pumps in youth with type 1 diabetes. Diabetes Technol Ther 2010, 12(Suppl 1):S59-S65.
• [77]Danne T, Battelino T, Jarosz-Chobot P, Kordonouri O, Pankowska E, Ludvigsson J, et al.: Establishing glycaemic control with continuous subcutaneous insulin infusion in children and adolescents with type 1 diabetes: experience of the PedPump Study in 17 countries. Diabetologia 2008, 51:1594-1601.
• [78]Pickup J: Insulin pumps. International journal of clinical practice Supplement 2011, 16-19.
• [79]Pickup JC, Renard E: Long-acting insulin analogs versus insulin pump therapy for the treatment of type 1 and type 2 diabetes. Diabetes Care 2008, 31(Suppl 2):S140-S145.
• [80]DiMeglio LA, Pottorff TM, Boyd SR, France L, Fineberg N, Eugster EA: A randomized, controlled study of insulin pump therapy in diabetic preschoolers. J Pediatr 2004, 145:380-384.
• [81]Weintrob N, Benzaquen H, Galatzer A, Shalitin S, Lazar L, Fayman G, et al.: Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens in children with type 1 diabetes: a randomized open crossover trial. Pediatrics 2003, 112:559-564.
• [82]Wilson DM, Buckingham BA, Kunselman EL, Sullivan MM, Paguntalan HU, Gitelman SE: A two-center randomized controlled feasibility trial of insulin pump therapy in young children with diabetes. Diabetes Care 2005, 28:15-19.
• [83]Nabhan ZM, Kreher NC, Greene DM, Eugster EA, Kronenberger W, DiMeglio LA: A randomized prospective study of insulin pump vs. insulin injection therapy in very young children with type 1 diabetes: 12-month glycemic, BMI, and neurocognitive outcomes. Pediatr Diabetes 2009, 10:202-208.
• [84]Shalitin S, Phillip M: The use of insulin pump therapy in the pediatric age group. Horm Res 2008, 70:14-21.
• [85]Bode BW, Tamborlane WV, Davidson PC: Insulin pump therapy in the 21st century. Strategies for successful use in adults, adolescents, and children with diabetes. Postgrad Med 2002, 111:69-77. quiz 27
• [86]Bode BW, Sabbah HT, Gross TM, Fredrickson LP, Davidson PC: Diabetes management in the new millennium using insulin pump therapy. Diabetes Metab Res Rev 2002, 18(Suppl 1):S14-S20.
• [87]Hofer SE, Heidtmann B, Raile K, Frohlich-Reiterer E, Lilienthal E, Berghaeuser MA, et al.: Discontinuation of insulin pump treatment in children, adolescents, and young adults. A multicenter analysis based on the DPV database in Germany and Austria. Pediatr Diabetes 2010, 11:116-121.
• [88]de Vries L, Grushka Y, Lebenthal Y, Shalitin S, Phillip M: Factors associated with increased risk of insulin pump discontinuation in pediatric patients with type 1 diabetes. Pediatr Diabetes 2011, 12:506-512.
• [89]Attia N, Jones TW, Holcombe J, Tamborlane WV: Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM. Diabetes Care 1998, 21:817-821.
• [90]Reichel A, Rietzsch H, Kohler HJ, Pfutzner A, Gudat U, Schulze J: Cessation of insulin infusion at night-time during CSII-therapy: comparison of regular human insulin and insulin lispro. Exp Clin Endocrinol Diabet Offic J German Soc Endocrinol German Diabet Assoc 1998, 106:168-172.
• [91]Egger M, Davey Smith G, Stettler C, Diem P: Risk of adverse effects of intensified treatment in insulin-dependent diabetes mellitus: a meta-analysis. Diabet Med J Brit Diabet Assoc 1997, 14:919-928.
• [92]Animas Vibe website. available from http://animascorp.co.uk/animasVibe webcite
• [93]Spring Zone pump website. available from http://www.springnow.com/index.aspx?id=4161 webcite
• [94]M A. Eight New Diabetes Products to Look For in 2012. 2011. available from http://asweetlife.org/a-sweet-life-staff/featured/eight-new-diabetes-products-to-look-for-in-2012/23195/ webcite
• [95]Tandem Diabetes website. available from http://www.tandemdiabetes.com/ webcite
• [96]Solo website. available from http://www.solo4you.com/ webcite
• [97]Cellnovo website. available from http://www.cellnovo.com/products.aspx webcite
• [98]Jewel PUMP Value for Life. available from http://www.debiotech.com/products/msys/insulinpump.html webcite
• [99]CNBC video: Medtronic CEO on Diabetes. available from http://video.cnbc.com/gallery/?video=1145719342 webcite
• [100]A T. Chasing the OmniPod: Patch Me If You Can. 2010. available from http://www.diabetesmine.com/2010/01/chasing-the-omnipod-patch-me-if-you-can.html webcite
• [101]H T. Spring - A Patch Pump Without a Motor. London, England, UK: Advanced Technologies & Treatments for Diabetes; 2011. accessed at http://www.springnow.com/uploadimages/Spring_Hybrid_Patch_Pump_ATTD_tech_presentation.pdf webcite
• [102]V-Go website. available from http://www.valeritas.com/vgo.shtml webcite
• [103]Finesse website. available from http://www.myfinesse.com/ webcite
• [104]Debiotech nanopump website. available from http://www.debiotech.com/products/msys/chronojet.html webcite
• [105]Anhalt H, Bohannon NJ: Insulin patch pumps: their development and future in closed-loop systems. Diabetes Technol Ther 2010, 12(Suppl 1):S51-S58.
• [106]Spring Universal Infusion Set. available from http://www.springnow.com/infusion-set.html webcite
• [107]Mastrandrea LD: Inhaled insulin: overview of a novel route of insulin administration. Vasc Health Risk Manag 2010, 6:47-58.
• [108]Harsch IA: Inhaled insulins: their potential in the treatment of diabetes mellitus. Treat Endocrinol 2005, 4:131-138.
• [109]Becquemin MH, Chaumuzeau JP: Inhaled insulin: a model for pulmonary systemic absorption? Rev Mal Respir 2010, 27:e54-e65.
• [110]Heinemann L: New ways of insulin delivery. International journal of clinical practice Supplement 2011, 31-46.
• [111]Potocka E, Baughman RA, Derendorf H: Population pharmacokinetic model of human insulin following different routes of administration. J Clin Pharmacol 2011, 51:1015-1024.
• [112]Inhaled insulin no longer marketed: discontinuation: Welcome news. Prescrire Int 2008, 17:139.
• [113]Neumiller JJ, Campbell RK, Wood LD: A review of inhaled technosphere insulin. Ann Pharmacother 2010, 44:1231-1239.
• [114]Hisasue J, Fukuyama S, Nakagaki N, Moriwaki A, Inoue S, Sakurada N, et al.: Inhalative administration of insulin using a new bubble jet atomization device. Fukuoka Igaku Zasshi Hukuoka Acta Med 2011, 102:215-222.
• [115]Depreter F, Burniat A, Blocklet D, Lacroix S, Cnop M, Fery F, et al.: Comparative pharmacoscintigraphic and pharmacokinetic evaluation of two new formulations of inhaled insulin in type 1 diabetic patients. Eur J Pharm Biopharm Offic J Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV 2012, 80:4-13.
• [116]Pozzilli P, Raskin P, Parkin CG: Review of clinical trials: update on oral insulin spray formulation. Diabetes Obes Metab 2010, 12:91-96.
• [117]Warnken M, Reitzenstein U, Sommer A, Fuhrmann M, Mayer P, Enzmann H, et al.: Characterization of proliferative effects of insulin, insulin analogues and insulin-like growth factor-1 (IGF-1) in human lung fibroblasts. Naunyn Schmiedebergs Arch Pharmacol 2010, 382:511-524.
• [118]Lasagna-Reeves CA, Clos AL, Midoro-Hiriuti T, Goldblum RM, Jackson GR, Kayed R: Inhaled insulin forms toxic pulmonary amyloid aggregates. Endocrinology 2010, 151:4717-4724.
• [119]R E, E A, Y M, M K: Evaluation of the safety and efficacy of two oral insulin formulations in healthy volunteers (poster presentation). Burlingame, CA: Eleventh Annual Diabetes Technology Meeting; 2011.
• [120]Clement S, Dandona P, Still JG, Kosutic G: Oral modified insulin (HIM2) in patients with type 1 diabetes mellitus: results from a phase I/II clinical trial. Metab Clin Exp 2004, 53:54-58.
• [121]Card JW, Magnuson BA: A review of the efficacy and safety of nanoparticle-based oral insulin delivery systems. Am J Physiol Gastrointest Liver Physiol 2011, 301:G956-G967.
• [122]Wong TW: Design of oral insulin delivery systems. J Drug Target 2010, 18:79-92.
• [123]Yadav N, Morris G, Harding SE, Ang S, Adams GG: Various non-injectable delivery systems for the treatment of diabetes mellitus. Endocr Metab Immune Disord Drug Targets 2009, 9:1-13.
• [124]Rastogi R, Anand S, Koul V: Electroporation of polymeric nanoparticles: an alternative technique for transdermal delivery of insulin. Drug Dev Ind Pharm 2010, 36:1303-1311.
• [125]Prelude SkinPrep system website. (available from http://www.echotx.com/drug-delivery.shtml webcite). pp. skin prep for insulin patches
• [126]Drug delivery in diabetes: making effective treatment tolerable ONdrugDELIVERY. available from http://www.ondrugdelivery.com/publications/diabetes.pdf webcite
• [127]Qin G, Gao Y, Wu Y, Zhang S, Qiu Y, Li F, et al.: Simultaneous basal-bolus delivery of fast-acting insulin and its significance in diabetes management. Nanomed Nanotechnol Biol Med 2012, 8:221-227.
• [128]J C. Smart insulin: J C. Smart insulin. 2008. available from http://www.technologyreview.com/biomedicine/21613/page1/ webcite
• [129]A N. Merck acquires diabetes specialist SmartCells for smart insulin tech. 2010. available from http://www.smartplanet.com/blog/smart-takes/merck-acquires-diabetes-specialist-smartcells-for-smart-insulin-tech/12731 webcite